JP2011527330A5 - - Google Patents

Download PDF

Info

Publication number
JP2011527330A5
JP2011527330A5 JP2011517242A JP2011517242A JP2011527330A5 JP 2011527330 A5 JP2011527330 A5 JP 2011527330A5 JP 2011517242 A JP2011517242 A JP 2011517242A JP 2011517242 A JP2011517242 A JP 2011517242A JP 2011527330 A5 JP2011527330 A5 JP 2011527330A5
Authority
JP
Japan
Prior art keywords
malic acid
sunitinib
iii
mixture
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011517242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011527330A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2009/050818 external-priority patent/WO2010004339A1/en
Publication of JP2011527330A publication Critical patent/JP2011527330A/ja
Publication of JP2011527330A5 publication Critical patent/JP2011527330A5/ja
Pending legal-status Critical Current

Links

JP2011517242A 2008-07-10 2009-07-09 スニチニブリンゴ酸塩の結晶形の調製方法 Pending JP2011527330A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1193/KOL/2008 2008-07-10
IN1193KO2008 2008-07-10
PCT/GB2009/050818 WO2010004339A1 (en) 2008-07-10 2009-07-09 Processes for the preparation of crystalline forms of sunitinib malate

Publications (2)

Publication Number Publication Date
JP2011527330A JP2011527330A (ja) 2011-10-27
JP2011527330A5 true JP2011527330A5 (enExample) 2012-08-23

Family

ID=41100787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517242A Pending JP2011527330A (ja) 2008-07-10 2009-07-09 スニチニブリンゴ酸塩の結晶形の調製方法

Country Status (7)

Country Link
US (1) US20110257237A1 (enExample)
EP (1) EP2297138A1 (enExample)
JP (1) JP2011527330A (enExample)
CN (1) CN102203085A (enExample)
AU (1) AU2009269768A1 (enExample)
CA (1) CA2730079A1 (enExample)
WO (1) WO2010004339A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2315764A2 (en) * 2008-08-25 2011-05-04 Generics [UK] Limited Crystalline form of sunitinib and processes for its preparation
US20120271056A1 (en) * 2009-11-12 2012-10-25 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
CA2788709A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
ES2709110T3 (es) 2012-03-23 2019-04-15 Laurus Labs Ltd Un proceso mejorado para la preparación de sunitinib y sus sales de adición de ácido
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技(北京)有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN105085490A (zh) * 2014-05-09 2015-11-25 上海科胜药物研发有限公司 新的舒尼替尼苹果酸盐晶型及其制备方法
CN115057814A (zh) * 2021-12-07 2022-09-16 山东新时代药业有限公司 一种米力农苹果酸盐晶体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000002I1 (de) * 2000-02-15 2008-04-17 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
EP2332934B1 (en) * 2001-08-15 2017-03-01 Pharmacia & Upjohn Company LLC Processes for the preparation of crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide.
CN1758914A (zh) * 2003-02-24 2006-04-12 苏根公司 用吲哚啉酮化合物治疗过度骨质溶解
US20040209937A1 (en) * 2003-02-24 2004-10-21 Sugen, Inc. Treatment of excessive osteolysis with indolinone compounds
EP2253629A1 (en) * 2007-11-21 2010-11-24 Teva Pharmaceutical Industries Ltd. Polymorphs of racemic sunitinib malate, compositions containing them and preparation thereof

Similar Documents

Publication Publication Date Title
JP2011527330A5 (enExample)
JP2017505329A5 (enExample)
JP2018520178A5 (enExample)
CN102827153B (zh) 阿齐沙坦的晶型及其制备方法
CN104311536A (zh) 一种制备来那度胺的方法
CN101768150A (zh) 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法
CN104140414B (zh) 阿昔替尼晶型的制备方法
CN106866767A (zh) 一种醋酸甲地孕酮的制备方法
WO2017092702A1 (zh) 奥贝胆酸晶型ⅱ及其制备方法和用途
CN105315258A (zh) 富马酸沃诺拉赞多晶型及其制备方法
CN106316986A (zh) 一种1-[2-(2,4-二甲基苯基硫烷基)苯基]哌嗪氢溴酸盐α型晶体的制备方法
CN104387366A (zh) 泊马度胺制备方法
CN104387421A (zh) 阿德福韦酯一水合物及其制备方法
CN104151251A (zh) 一种一锅合成5-乙酰乙酰氨基苯并咪唑酮的方法
CN109134571B (zh) 一种17-碘-雄甾-5,16-二烯-3β-醇的制备方法
CN103910685A (zh) 一种提纯周效磺胺的方法
CN102838586A (zh) 一种制备来那度胺的方法
CN102219777B (zh) 制备雷贝拉唑钠的方法
CN106749060B (zh) 一种帕托珠利的精制方法
CN102838649A (zh) 一种醋酸阿比特龙的制备方法
CN104693177A (zh) 一种埃索美拉唑钠的精制方法
CN105237529A (zh) 高纯度无水达沙替尼的精制方法
CN104529864A (zh) 一种醋酸巴多昔芬晶型a的制备方法
WO2015151190A1 (ja) イルソグラジンマレイン酸塩の製造方法
CN103058996B (zh) 一种氮杂环类化合物的制备方法及其用途